T-cell prolymphocytic leukemia: survival improves with alemtuzemab but stem cell transplant eligibility "counts"even more.

LEUKEMIA & LYMPHOMA(2016)

引用 2|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要